CoChat
Sign Up
Cited by 155Blood Pressure and Hypertension StudiesDialysis and Renal Disease ManagementRenal and Vascular Pathologies

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Feasibility of catheter-based renal nerve ablation and effects on sympathetic nerve activity and blood pressure in patients with end-stage renal disease

Schlaich, Markus P., Bart, Bradley, Hering, Dagmara, Walton, Anthony, Marusic, Petra, Mahfoud, Felix, Böhm, Michael, Lambert, Elisabeth A., Krum, Henry, Sobotka, Paul A., Schmieder, Roland E., Ika-Sari, Carolina, Eikelis, Nina, Straznicky, Nora, Lambert, Gavin W., Esler, Murray D.·2013·International Journal of Cardiology
DOI 10.1016/j.ijcard.2013.01.218
Open this paper in CoChat — free account

Abstract

Background and objectives Sympathetic activation is a hallmark of ESRD and adversely affects cardiovascular prognosis. Efferent sympathetic outflow and afferent neural signalling from the failing native kidneys are key mediators and can be targeted by renal denervation (RDN). Whether this is feasible and effective in ESRD is not known.Design, setting, participants and measurements In an initial safety and proof-of-concept study we attempted to perform RDN in 12 patients with ESRD and uncontrolled blood pressure (BP). Standardized BP measurements were obtained in all patients on dialysis free days at baseline and follow up. Measures of renal noradrenaline spillover and muscle sympathetic nerve activity were available from 5 patients at baseline and from 2 patients at 12 month follow up and beyond.Results Average office BP was 170.8 ± 16.9/89.2 ± 12.1 mmHg despite the use of 3.8 ± 1.4 antihypertensive drugs. All 5 patients in whom muscle sympathetic nerve activity and noradrenaline spillover was assessed at baseline displayed substantially elevated levels. Three out of 12 patients could not undergo RDN due to atrophic renal arteries. Compared to baseline, office systolic BP was significantly reduced at 3, 6, and 12 months after RDN (from 166 ± 16.0 to 148 ± 11, 150 ± 14, and 138 ± 17 mmHg, respectively), whereas no change was evident in the 3 non-treated patients. Sympathetic nerve activity was substantially reduced in 2 patients who underwent repeat assessment.Conclusions RDN is feasible in patients with ESRD and associated with a sustained reduction in systolic office BP. Atrophic renal arteries may pose a problem for application of this technology in some patients with ESRD.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.ijcard.2013.01.218

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 30 references

Cited by

Sorted by citations

Items 101–155 of 155

Related

See all

Metadata

Authors
Schlaich, M. P., Bart, B., Hering, D., Walton, A., Marusic, P., Mahfoud, F., Böhm, M., Lambert, E. A., Krum, H., Sobotka, P. A., Schmieder, R. E., Ika-Sari, C., Eikelis, N., Straznicky, N., Lambert, G. W., & Esler, M. D.
Affiliations
  • Baker Heart and Diabetes Institute (AU)
  • University of Minnesota (US)
  • The Alfred Hospital (AU)
  • Universitätsklinikum des Saarlandes (DE)
  • Monash University (AU)
  • Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
ORCID
Venue
International Journal of Cardiology
Publisher
Elsevier BV
Published
2013-10
Volume
168
Issue
3
Pages
2214-2220
ISSN
0167-5273 (ISSN-L)
DOI
10.1016/j.ijcard.2013.01.218
OpenAlex
W2065121034
Cited by
155
References
30
Citations by year
2026: 8 · 2025: 7 · 2024: 4 · 2023: 8 · 2022: 5 · 2021: 4 · 2020: 8 · 2019: 2 · 2018: 2 · 2017: 11 · 2016: 21 · 2015: 20 · 2014: 33 · 2013: 21
FWCI
21.62
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • International Journal of Cardiology (publishedVersion)
  • PubMed (publishedVersion)
  • Swinburne figshare (Swinburne University of Technology) (submittedVersion)
Funders
  • Australian Government
  • State Government of Victoria
  • National Health and Medical Research Council
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
  • Health Sciences › Medicine › Nephrology › Dialysis and Renal Disease Management
  • Health Sciences › Medicine › Nephrology › Renal and Vascular Pathologies
Keywords
renal denervation, renal nerve ablation, end-stage renal disease, uncontrolled hypertension, blood pressure reduction, muscle sympathetic nerve activity, noradrenaline spillover, sympathetic nervous system, dialysis, cardiovascular risk
MeSH terms
Blood Pressure, Feasibility Studies, Female, Follow-Up Studies, Humans, Hypertension, Renal, Kidney, Kidney Failure, Chronic, Male, Middle Aged, Sympathectomy, Sympathetic Nervous System, Time Factors, Treatment Outcome, Catheter Ablation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review